Cargando…

Concerns Regarding the Use of Dabigatran for Stroke Prevention in Atrial Fibrillation

Dabigatran is an oral thrombin inhibitor which has been approved in several countries as an alternative to vitamin-K-antagonists for the prevention of stroke or embolism in atrial fibrillation patients. Dabigatran is introduced into clinical practice, although many issues regarding this drug are sti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stöllberger, Claudia, Finsterer, Josef
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2012
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3763635/ https://www.ncbi.nlm.nih.gov/pubmed/24288086 http://dx.doi.org/10.3390/ph5020155

Ejemplares similares

Stroke prevention in an octogenarian with atrial fibrillation, cerebral amyloid angiopathy and intracerebral hemorrhage
por: Stöllberger, Claudia, et al.
Publicado: (2023)

Practical use of dabigatran etexilate for stroke prevention in atrial fibrillation
por: Huber, K, et al.
Publicado: (2013)

The clinical efficacy of dabigatran etexilate for preventing stroke in atrial fibrillation patients
por: Ellis, Christopher R, et al.
Publicado: (2013)

Lift the quilt in case of atrial fibrillation and disc prolapse
por: Bastovansky, Adam, et al.
Publicado: (2012)

Dabigatran for Stroke Prevention in Nonvalvular Atrial Fibrillation: Answers to Challenging “Real-World” Questions
por: Ferreira, Jorge, et al.
Publicado: (2012)

Stroke Prevention in Atrial Fibrillation: Understanding the New Oral Anticoagulants Dabigatran, Rivaroxaban, and Apixaban
por: Ru San, Tan, et al.
Publicado: (2012)

Economic Evaluation of Warfarin, Dabigatran, Rivaroxaban, and Apixaban for Stroke Prevention in Atrial Fibrillation
por: Wisløff, Torbjørn, et al.
Publicado: (2014)

Cost of dabigatran for atrial fibrillation
por: Gage, Brian F
Publicado: (2011)

Traumatic fatal cerebral hemorrhage in an old patient with a history of multiple sclerosis under dabigatran: a case report and review of the literature
por: Stöllberger, Claudia, et al.
Publicado: (2015)

FDA committee unanimously recommends approval of dabigatran etexilate for stroke prevention in atrial fibrillation
por: J, Aalbers, et al.
Publicado: (2010)

Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation
por: Kansal, Anuraag R, et al.
Publicado: (2012)

Adherence to Rivaroxaban, Dabigatran, and Apixaban for Stroke Prevention in Incident, Treatment-Naïve Nonvalvular Atrial Fibrillation
por: Brown, Joshua D., et al.
Publicado: (2016)

Stroke prevention in atrial fibrillation changes after dabigatran availability in China: The GLORIA‐AF registry
por: Ma, Changsheng, et al.
Publicado: (2020)

Cost‐effectiveness analysis of dabigatran, rivaroxaban and warfarin in the prevention of stroke in patients with atrial fibrillation in China
por: Wei, Hongtao, et al.
Publicado: (2021)

A Comparative Analysis of Models Used to Evaluate the Cost-Effectiveness of Dabigatran Versus Warfarin for the Prevention of Stroke in Atrial Fibrillation
por: Sorensen, Sonja V., et al.
Publicado: (2013)

Letter to the Editor Regarding: What Triggers Takotsubo After a SARS-CoV-2 Vaccination? Heart Lung Circ. 2021;30(12):e119–20
por: Finsterer, Josef, et al.
Publicado: (2022)

Massive Left Atrial Thrombi during Dabigatran Therapy for Nonvalvular Atrial Fibrillation
por: Bachvarova, Velislava, et al.
Publicado: (2017)

Cost-Effectiveness of Dabigatran versus Genotype-Guided Management of Warfarin Therapy for Stroke Prevention in Patients with Atrial Fibrillation
por: You, Joyce H. S., et al.
Publicado: (2012)

Risk factors and prevention of dabigatran‐related gastrointestinal bleeding in patients with atrial fibrillation
por: Nantsupawat, Teerapat, et al.
Publicado: (2017)

Dabigatran in patients with atrial fibrillation: perioperative and periinterventional management
por: Weltermann, A., et al.
Publicado: (2012)

Prevent Sudden Death in Carvajal Syndrome With Left Ventricular Hypertrabeculation/Noncompaction
por: Stollberger, Claudia, et al.
Publicado: (2016)

Treatment Persistence and Discontinuation with Rivaroxaban, Dabigatran, and Warfarin for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation in the United States
por: Coleman, Craig I., et al.
Publicado: (2016)

Survey of the use of warfarin and the newer anticoagulant dabigatran in patients with atrial fibrillation
por: Choi, Jiyoon C, et al.
Publicado: (2014)

Takotsubo syndrome in a stroke patient with carotid artery stenosis
por: Stöllberger, Claudia, et al.
Publicado: (2018)

Dabigatran Versus Warfarin for Direct Current Cardioversion in Atrial Fibrillation
por: Benamer, Sufyan, et al.
Publicado: (2016)

Comparative Effectiveness and Safety of Dabigatran and Rivaroxaban in Atrial Fibrillation Patients
por: Lai, Chao‐Lun, et al.
Publicado: (2017)

Arrhythmogenic Right Ventricular Dysplasia in Neuromuscular Disorders
por: Finsterer, Josef, et al.
Publicado: (2016)

Atrial Fibrillation and Stroke Symptoms in the REGARDS Study
por: Reading Turchioe, Meghan, et al.
Publicado: (2022)

Dabigatran in patients with atrial fibrillation after COVID-19 hospitalization: an update of the ANIBAL protocol
por: Cerezo-Manchado, Juan José, et al.
Publicado: (2022)

Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study
por: Sørensen, Rikke, et al.
Publicado: (2013)

Heart Disease in Disorders of Muscle, Neuromuscular Transmission, and the Nerves
por: Finsterer, Josef, et al.
Publicado: (2016)

Left Atrial Appendage Occlusion for Stroke Prevention in Nonvalvular Atrial Fibrillation
por: Collado, Fareed Moses S., et al.
Publicado: (2021)

Emerging Tools for Stroke Prevention in Atrial Fibrillation
por: Voukalis, Christos, et al.
Publicado: (2016)

Non-Pharmacological Stroke Prevention in Atrial Fibrillation
por: Anduaga, Iñigo, et al.
Publicado: (2023)

Effects of uninterrupted dabigatran on the intensity of anticoagulation during atrial fibrillation ablation
por: Osawa, Takumi, et al.
Publicado: (2021)

Post-marketing surveillance on the long-term use of dabigatran in Japanese patients with nonvalvular atrial fibrillation: Preliminary report of the J-dabigatran surveillance
por: Inoue, Hiroshi, et al.
Publicado: (2016)

Myotonic dystrophy patients: More data about cardiac and neurologic findings would be useful
por: Stöllberger, Claudia, et al.
Publicado: (2021)

Left Atrial Appendage Closure to Prevent Strokes and Ligation to Prevent Atrial Fibrillation
por: Ellis, Christopher R.
Publicado: (2017)

Left Atrial Appendage Exclusion for Stroke Prevention in Atrial Fibrillation
por: Patel, Taral K., et al.
Publicado: (2012)

Stroke Prevention in Atrial Fibrillation: Where are We Now?
por: Ahmad, Yousif, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_ih6btjlrpno3plff4qnuldbp4g